On January 18, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022) ("National Reimbursement Drug List"). The first-line indication of Ameile (Aumolertinib Mesilate Tablets) and the rare disease drug Xinyue (Inebilizumab Injection) were successfully added to the National Reimbursement Drug List, and two other innovative were successfully renewed. Up to now, Hansoh Pharma's all six innovative drugs available in the market have been included in the National Reimbursement Drug List.

Ameile, a medically insured drug for first-line treatment of NSCLC

Ameile is an EFGR mutated non-small cell lung cancer (NSCLC) targeted drug developed by Hansoh Pharma, and also China's first original third-generation EGFR-TKI. In March 2020, the first indication of Ameile was approved for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC who have experienced disease progression on or after prior EGFR-TKI therapy, and only nine months later, Ameile was successfully added to the National Reimbursement Drug List. In December 2021, Ameile was approved for the indication of first-line treatment of locally advanced or metastatic NSCLC with EGFR-sensitive mutations, officially opening a brand-new era of first-line treatment with China's original third-generation EGFR-TKI. With the inclusion of both indications in the National Reimbursement Drug List, Chinese NSCLC patients will have greater access to the drug.

Xinyue, the first and only medically insured drug for NMOSD patients

Xinyue (Inebilizumab Injection) is currently the only humanized anti-CD19 monoclonal antibody approved for the treatment of adult patients with AQP4 antibody positive neuromyelitis optica spectrum disorders (NMOSD) worldwide. NMOSD is a rare neurological autoimmune disease, and Chinese patients are currently faced with a severe drug accessibility challenge due to the lack of definite therapeutic drugs. Introduced by Hansoh Pharma and included in the National Reimbursement Drug List, Xinyue, as the first and only medically insured drug for NMOSD, will significantly improve the accessibility, affordability and standardization of clinical treatment for NMOSD patients in China, helping patients to reduce relapse, minimize disability and return to normal life.

Successful renewal of Hansoh Xinfu and Fulaimei in the National Reimbursement Drug List

Hansoh Pharma has always been patient-focused and concerned about patients' access to medication. Hansoh Pharma's first Chinese original chronic myeloid leukemia (CML) drug Hansoh Xinfu (Flumatinib Mesylate Tablets) and first Chinese original long-acting GLP-1 hypoglycemic drug Fulaimei (Polyethylene Glycol Loxenatide Injection) have been successfully renewed in the National Reimbursement Drug List through negotiation. Up to now, all six innovative drugs of Hansoh Pharma have been included in the National Reimbursement Drug List, which will help improve the accessibility and affordability of innovative drugs in China for the benefit of more Chinese patients.